Rigel Pharma Analyst Day saw 85% tavalisse refill rate, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $8 price target on Righer Pharmaceuticals after the company’s Analyst Day. He says the presentation indicated utilization of Tavalisse across all lines and a 85% refill rate, suggesting that the drug had higher demand than anticipated. Raymond contends that the launch so far has been successful while also pointing to the company’s “positive progress for fostamatinib in AIHA and other pipeline products”.
https://thefly.com/landingPageNews.php?id=2800113